An analysis of the health service efficiency and patient experience with two different intravenous iron preparations in a UK anaemia clinic

Journal of Medical Economics

Volumn 16, Issue 1, 2013, Pages 108-114

  Wilson, Paul D ^a   Hutchings, Adam ^b   Jeans, Aruna ^c   Macdougall, Iain C ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

^b GMAS LLP   (United Kingdom)

^c UK)   (United Kingdom)

Author keywords

Ferric carboxymaltose; Ferric oxide saccharated; Healthcare costs; Iron; Patient centred care; Renal insufficiency (chronic)

Indexed keywords

FERRIC CARBOXYMALTOSE; IRON SACCHARATE;

ANEMIA; ARTICLE; BIOEQUIVALENCE; DRUG COST; HEALTH CARE COST; HEALTH SERVICE; PATIENT TRANSPORT; PERSONAL EXPERIENCE; UNITED KINGDOM;

ADMINISTRATION, INTRAVENOUS; AMBULATORY CARE FACILITIES; ANEMIA, IRON-DEFICIENCY; CLINICAL PROTOCOLS; COSTS AND COST ANALYSIS; DECISION SUPPORT TECHNIQUES; EFFICIENCY, ORGANIZATIONAL; FERRIC COMPOUNDS; GLUCARIC ACID; GREAT BRITAIN; HEMATINICS; HOSPITALIZATION; HUMANS; MALTOSE; PATIENT PREFERENCE; RENAL INSUFFICIENCY, CHRONIC; TRANSPORTATION;

EID: 84870881263     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2012.731458     Document Type: Article

References (29)

1. McClellan W, Aronoff SL, Bolton WK, et al. The prevalence of anemia in patients with chronic kidney disease. Curr Med Res Opin 2004;20:1501-10 (Pubitemid 39361354)
2. Schmidt RJ, Dalton CL. Treating anemia of chronic kidney disease in the primary care setting: Cardiovascular outcomes and management recommendations. Osteopath Med Prim Care 2007;1:14
3. Lefebvre P, Duh MS, Buteau S, et al. Medical costs of untreated anemia in elderly patients with predialysis chronic kidney disease. J Am Soc Nephrol 2006;17:3497-502 (Pubitemid 44865292)
4. National Institute for Health and Clinical Excellence (NICE). Anaemia management in people with chronic kidney disease. 2011. http://www.nice.org.uk/ CG114. Accessed May 6, 2011
5. O'Mara NB. Anemia in patients with chronic kidney disease. Diabetes Spectrum 2008;21:12-9 (Pubitemid 351354200)
6. Bernhardt WM, Wiesener MS, Scigalla P, et al. Inhibition of prolyl hydroxylases increases erythropoietin production in ESRD. J Am Soc Nephrol 2010;21:2151-6
7. Gotloib L, Silverberg D, Fudin R, et al. Iron deficiency is a common cause of anemia in chronic kidney disease and can often be corrected with intravenous iron. J Nephrol 2006;19:161-7 (Pubitemid 44420105)
8. Fishbane S, Pollack S, Feldman HI, et al. Iron indices in chronic kidney disease in the National Health and Nutritional Examination Survey 1988-2004. Clin J Am Soc Nephrol 2009;4:57-61
9. Valderrabano F, Horl WH, Macdougall IC, et al. PRE-dialysis survey on anaemia management. Nephrol Dial Transplant 2003;18:89-100 (Pubitemid 36104483)
10. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med 2005;352:1011-23
11. Macdougall IC, Hutton RD, Cavill I, et al. Poor response to treatment of renal anaemia with erythropoietin corrected by iron given intravenously. BMJ 1989;299:157-8 (Pubitemid 19186661)
12. Macdougall IC. Strategies for iron supplementation: Oral versus intravenous. Kidney Int Suppl 1999;69:S61-6 (Pubitemid 29113585)
13. Charytan C, Qunibi W, Bailie GR. Comparison of intravenous iron sucrose to oral iron in the treatment of anemic patients with chronic kidney disease not on dialysis. Nephron Clin Pract 2005;100:c55-c62 (Pubitemid 40868986)
14. Locatelli F, Aljama P, Barany P, et al. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 2004;19(2 Suppl):ii1-47
15. Mircescu G, Garneata L, Capusa C, et al. Intravenous iron supplementation for the treatment of anaemia in pre-dialyzed chronic renal failure patients. Nephrol Dial Transplant 2006;21:120-4 (Pubitemid 43057119)
16. Van Wyck DB, Roppolo M, Martinez CO, et al. A randomized, controlled trial comparing IV iron sucrose to oral iron in anemic patients with nondialysisdependent CKD. Kidney Int 2005;68:2846-56 (Pubitemid 43251032)
17. Bager P, Dahlerup JF. The health care cost of intravenous iron treatment in IBD patients depends on the economic evaluation perspective. J Crohns Colitis 2010;4:427-30
18. Szucs TD, Blank PR, Schwenkglenks M. Health economic impact of intravenous iron supplementation in anaemia treatment with erythropoiesis- stimulating agents. 2009. Poster presented at European Hematology Association Congress (0135), Berlin, Germany
19. Szucs TD, Blank PR, Schwenkglenks M, et al. Potential health economic impact of intravenous iron supplementation to erythropoiesis-stimulating agent treatment in patients with cancer- or chemotherapy-induced anemia. Oncology 2011;81:45-9
20. Tagboto S, Cropper L, Turner J, et al. The efficacy of a single dose of intravenous ferric carboxymaltose (Ferinject) on anaemia in a predialysis population of chronic kidney disease patients. J Ren Care 2009; 35:18-23
21. Macdougall IC, Roche A. Administration of intravenous iron sucrose as a 2- minute push to CKD patients: A prospective evaluation of 2,297 injections. Am J Kidney Dis 2005;46:283-9 (Pubitemid 41040357)
22. Vifor Pharma. Ferinject summary of product characteristics. 2011 http://www.medicines.org.uk/EMC/medicine/24167/SPC/Ferinject(ferric carboxymaltose)/. Accessed March 19, 2010
23. NHS Careers. NHS pay - agenda for change - pay rates. 2011 http://www.nhscareers.nhs.uk/details/default.aspx?Id766. Accessed May 6, 2011
24. British Medical Association and the Royal Pharmaceutical Society of Great Britain. British National Formulary (BNF) 62. London: BMJ Group and Pharmaceutical Press, 2011
25. King's College Hospital data: 2010 Transport for London. Fares. 2011. http://www.tfl.gov.uk/tickets/ 14416.aspx. Accessed June 27, 2011
26. Pugh-Clarke K, Cooper L, Turner J, et al. An evidence-based approach to anaemia management in predialysis chronic kidney disease. J Ren Care 2009;35(2 Suppl):29-31
27. Grimmelt AC, Cohen CD, Fehr T, et al. Safety and tolerability of ferric carboxymaltose (FCM) for treatment of iron deficiency in patients with chronic kidney disease and in kidney transplant recipients. Clin Nephrol 2009;71:125-9
28. Bhandari S. A hospital-based cost minimization study of the potential financial impact on the UK health care system of introduction of iron isomaltoside 1000. Ther Clin Risk Manag 2011;7:103-13
29. Brock E, Braunofer P, Troxler J, et al. Real-life budget impact (BI) of parenteral iron treatment of iron deficiency in Switzerland. 2010. Poster presented at ISPOR (PSY12). Prague, Czech Republic Office for National Statistics. Labour market statistics April 2011. 2011 http://www.ons.gov.uk/ons/ search/index.html?pageSize50&newquery LabourStatisticsbulletinApril. Accessed May 6, 2011